Skip to main
INSM
INSM logo

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 60%
Buy 33%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Insmed Inc. is experiencing a positive shift in financial outlook, driven by increased revenue estimates for its key product Brensocatib (Brinsupri NCFB) and anticipated contributions from Treprostinil Palmitil Inhalation Powder (TPIP). The projected worldwide sales for Brensocatib have been raised to approximately $8.5 billion by 2033, reflecting heightened confidence in its near- and long-term potential. Additionally, the company has reduced its terminal decline rate in its discounted cash flow (DCF) calculations, further underscoring positive expectations for the sustainability of its product pipeline.

Bears say

Insmed Inc faces potential delays in the enrollment and completion of clinical studies for its products, ARIKAYCE, brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP), which could severely impact the company's probability of success and overall valuation. The lengthy timelines indicated by competitors suggest that TPIP may not enter the idiopathic pulmonary fibrosis (IPF) market until at least 2034, contingent upon regulatory approvals in 2027. Such uncertainties around product approval and market entry timelines raise concerns about Insmed's ability to capitalize on its product pipeline effectively, contributing to a negative financial outlook for the company.

Insmed (INSM) has been analyzed by 15 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 33% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 15 analysts, Insmed (INSM) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $188.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $188.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.